Matrixyl 3000 (Palmitoyl Tripeptide-1 + Tetrapeptide-7)
Matrixyl 3000 is a patented topical cosmetic peptide complex developed by the French active-ingredient manufacturer Sederma (a Croda company). It combines two lipid-modified synthetic "matrikine" peptides: Palmitoyl Tripeptide-1 (palmitic acid linked to the Gly-His-Lys / GHK sequence, a fragment of type I collagen) and Palmitoyl Tetrapeptide-7 (palmitic acid linked to the Gly-Gln-Pro-Arg / GQPR sequence). The palmitic-acid (C16 fatty acid) tail increases lipophilicity to help the peptides cross the skin's lipid barrier. It is the successor complex to the original Matrixyl (Palmitoyl Pentapeptide-4, Pal-KTTKS, launched by Sederma in 2000) and is used at low concentrations in leave-on cosmetic skincare such as serums and creams.
Education only. This page summarises published research on a cosmetic or dietary ingredient. It is not medical advice and makes no treatment claims; for a finished product, follow its label.
- Also known as
- Matrixyl 3000, Pal-GHK + Pal-GQPR, Palmitoyl Tripeptide-1 (Pal-GHK), Palmitoyl Tetrapeptide-7 (Pal-GQPR), Palmitoyl Oligopeptide + Palmitoyl Tetrapeptide-7 (older INCI naming), Sederma Matrixyl 3000
- Class
- Topical matrikine / messenger-peptide complex (lipidated synthetic signal peptides). Palmitoyl Tripeptide-1 is a palmitoylated Gly-His-Lys (GHK) collagen-fragment matrikine; Palmitoyl Tetrapeptide-7 is a palmitoylated Gly-Gln-Pro-Arg (GQPR) anti-inflammatory matrikine.
How does Matrixyl 3000 work?
Matrikines are small peptide fragments released when the skin's extracellular matrix (ECM) is broken down; the body reads them as a "repair needed" signal that prompts dermal fibroblasts to make new matrix. Matrixyl 3000's peptides are synthetic mimics of these fragments. Palmitoyl Tripeptide-1 (GHK-based) signals fibroblasts to upregulate synthesis of collagen (types I, III, IV and others), fibronectin and other ECM components, in effect prompting a skin remodeling/repair response without actual injury. Palmitoyl Tetrapeptide-7 (GQPR) is thought to dampen interleukin-6 (IL-6)-driven low-grade inflammation ("inflammaging") that drives matrix-metalloproteinase (MMP) activity, helping protect existing and newly made collagen from premature breakdown. The two are designed to act synergistically: build new matrix while reducing inflammatory degradation. Effects are topical/local in the skin; this is a cosmetic surface ingredient, not a systemic injectable.
What has Matrixyl 3000 been studied for?
- Appearance of fine lines and wrinkles (cosmetic anti-aging)
- Improving the look of skin firmness, elasticity and laxity
- Supporting dermal collagen/ECM in lab (fibroblast) and instrumental skin studies
- Skin smoothness, roughness and overall photoaged-skin appearance
- Eye-area appearance in combination eye-cream formulations
What does the evidence show?
Moderate but caveated. Mechanistic and in vitro evidence is reasonably strong: fibroblast/lab studies (and the foundational matrikine work of Lintner & Peschard, Int. J. Cosmetic Science, 2000) consistently show that GHK- and palmitoyl-peptide matrikines stimulate collagen, fibronectin and ECM synthesis. Clinical human evidence is more limited and largely cosmetic-grade rather than pharmaceutical-grade. The most-cited clinical anchor is for the predecessor peptide (Robinson et al., Int. J. Cosmetic Science, 2005: a 12-week double-blind split-face RCT of Pal-KTTKS at ~3 ppm showing significant reductions in wrinkle/fine-line appearance vs vehicle). For the exact Matrixyl 3000 pair, supportive data include Yang et al. 2024 (Skin Research and Technology, PMID 38932444), a fibroblast + 12-week clinical evaluation of a multi-component eye cream containing both peptides showing fibroblast proliferation and increased collagen/elastin plus improved skin parameters; and instrumental studies of palmitoyl-peptide formulations (e.g., PMC4950680) reporting measurable improvements in aged skin. KEY LIMITATIONS: many trials are small, manufacturer-funded or industry-adjacent, use multi-ingredient formulations (so the peptide's isolated contribution is hard to separate), are short (typically 4-12 weeks), measure appearance and instrumental proxies rather than long-term biopsy-confirmed structural change, and are subject to publication bias. Efficacy also depends heavily on formulation and skin penetration. Bottom line: credible cosmetic-grade evidence for improving the look of fine lines and skin quality; not pharmaceutical-grade proof of a clinical anti-aging "treatment," and results are not guaranteed and vary by individual and formulation.
What is known about the safety of Matrixyl 3000?
Generally regarded as well tolerated and low-risk as a topical cosmetic. The Cosmetic Ingredient Review (CIR) Expert Panel safety assessment covering Tripeptide-1, its fatty-acyl derivatives and Palmitoyl Tetrapeptide-7 concluded these ingredients are safe in cosmetics in the current practices of use and concentration; typical use levels are very low (on the order of <10 ppm), and the panel noted the low concentrations plus negative safety test data obviate safety concerns. Common practical considerations are limited to mild, infrequent topical reactions (irritation, redness, or rare contact sensitivity), as with most leave-on skincare; patch testing is sensible for reactive or allergy-prone skin. Caveats: long-term, large-population safety data specific to chronic use are limited; safety conclusions apply to topical cosmetic use, not to any off-label injection or oral use (which is not a studied or appropriate route for these ingredients). People who are pregnant, breastfeeding, or have an active skin condition should consult a clinician before adding new actives.
What is the legal status of Matrixyl 3000?
Legal to sell and use as a cosmetic ingredient in leave-on skincare in the US, EU and most markets; it is an established INCI-listed cosmetic ingredient, not a controlled or prescription substance. Under US law, cosmetics do not require FDA pre-market approval, but the FDA distinguishes cosmetics from drugs by intended use/claims: products meant to make wrinkles "look" less noticeable are cosmetics, whereas claims that a product alters skin structure or function (e.g., "stimulates collagen production," "removes wrinkles") can render it an unapproved new drug and trigger FDA enforcement. Matrixyl 3000 itself is not an FDA-approved drug. Not a WADA-prohibited substance in topical cosmetic use. Brand/marketing language must therefore stay in cosmetic, appearance-based terms.
What is the half-life of Matrixyl 3000?
Not characterized as a systemic pharmacologic half-life, because this is a topical, locally-acting cosmetic rather than a circulating drug. Free small peptides are generally short-lived and rapidly degraded by skin peptidases; the palmitic-acid (C16) modification improves stability and skin penetration relative to the unmodified peptide. No validated systemic plasma half-life is reported for normal cosmetic topical use.
Where to find Matrixyl 3000 at Peppies
Sources
- CIR Expert Panel — Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics (Johnson et al., Int J Toxicol, 2018)
- Yang et al., Comprehensive evaluation of the efficacy and safety of a new multi-component anti-aging topical eye cream (containing palmitoyl tripeptide-1 + palmitoyl tetrapeptide-7), Skin Research and Technology, 2024 — PMID 38932444
- Robinson et al., Topical palmitoyl pentapeptide (Pal-KTTKS) provides improvement in photoaged human facial skin — 12-week double-blind split-face RCT, International Journal of Cosmetic Science, 2005
- Lintner K. & Peschard O., Biologically active peptides: from a laboratory bench curiosity to a functional skin care product, International Journal of Cosmetic Science, 2000
- Instrumental evaluation of anti-aging effects of cosmetic formulations containing palmitoyl peptides on aged human skin, PMC4950680
- US FDA — Wrinkle Treatments and Other Anti-Aging Products (cosmetic vs drug classification)
- Wikipedia — Palmitoyl pentapeptide-4 (Matrixyl / Sederma background, INCI, matrikine mechanism)